

# Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

Company name: NICHIBAN CO., LTD.

Listing: Tokyo Stock Exchange

Securities code: 4218

# Consolidated Financial Results FY 3/2025



		Results FY 3/2025	Results FY 3/2024	YoY	Forecast FY 3/2025 (Before revision)	Forecast FY 3/2025 (After revision)	vs. Forecast (After revision)
Net sales	Millions of yen	49,457	46,859	+5.5%	48,600	49,000	+0.9%
Gross profit	Millions of yen	14,902	13,871	+7.4%	_	_	_
SG&A	Millions of yen	12,315	11,798	+4.4%	_	_	_
Operating profit	Millions of yen	2,586	2,073	+24.8%	2,400	2,700	-4.2%
Operating profit margin	%	5.2	4.4	+0.8pt	_	_	_
Ordinary profit	Millions of yen	2,681	2,201	+21.8%	2,500	2,800	-4.3%
Profit attributable to owners of parent	Millions of yen	1,959	1,827	+7.2%	1,900	2,100	-6.7%

# Consolidated Financial Results FY 3/2025



		1Q		2Q		3Q		4Q	
		Results	YoY	Results	YoY	Results	YoY	Results	YoY
Net sales	Millions of yen	11,524	+5.6%	12,234	+6.0%	13,625	+4.4%	12,072	+6.3%
Gross profit	Millions of yen	3,500	+8.1%	3,743	+17.4%	4,278	+2.8%	3,379	+3.0%
SG&A	Millions of yen	2,986	+3.3%	3,083	+2.6%	3,101	+4.1%	3,144	+7.7%
Operating profit	Millions of yen	514	+48.6%	660	+260.1%	1,177	-0.4%	235	-35.0%
Operating profit margin	%	4.5	+1.3pt	5.4	+3.8pt	8.6	-0.4pt	1.9	– 1.2pt
Ordinary profit	Millions of yen	587	+32.1%	640	+231.1%	1,200	-0.5%	254	-28.9%
Profit attributable to owners of parent	Millions of yen	333	+18.6%	476	+215.3%	862	-10.1%	287	-34.0%


# Consolidated Financial Results FY 3/2025



		FY 3/2021 Results	FY 3/2022 Results	FY 3/2023 Results	FY 3/2024 Results	3/2025 Results	3/2026 Forecast
Capital expenditures Millions of yen		2,755	3,981	4,092	1,803	1,043	3,618
<b>Depreciation</b> Millions of yen		2,342	2,545	2,757	2,795	3,145	2,869
R&D expenses	Millions of yen	1,064	1,057	1,110	1,202	1,345	1,478

# Analysis of Operating Profit





# Net sales



### **Domestic: Healthcare Products**

15,243 Millions of yen (+6.0%)

(YOY)

- CARELEAVES<sub>TM</sub> (+9.4%)
- ROIHI series (+0.2%)
- ■BATTLEWIN series (+3.8%)

### **Domestic: Stationery Products**

4,840 Millions of yen (-3.2%)

(YOY)

- Cellulose tape (±0%)
- NICETACK<sub>TM</sub> (-4.2%)

### **Domestic: EC**

5,250 Millions of yen (+13.1%)

(YOY)

- $\blacksquare$  Cellulose tape (+15.5%)
- NICETACK<sub>TM</sub> (+2.6%)
- CARELEAVES<sub>TM</sub> (+67.1%)

## **Domestic: Hospital Products**

5,740 Millions of yen (-0.2%)

(YOY)

- $\blacksquare$  Surgical tape (+0.5%)
- Hemostatic bandage (-1.2%)
- Wound care dressing (-2.0%)

### **Domestic: Industrial Products**

13,189 Millions of yen (+0.8%)

(YOY)

- Packaging tape (-0.4%)
- Masking tape (+4.8%)
- Tabanera<sub>TM</sub> tape (-0.9%)

### Global

5,192 Millions of yen (+29.9%)

(YOY)

- $\blacksquare$  CARELEAVES<sub>TM</sub> (+88.2%)
- Hemostatic bandage (+39.9%)
- Panfix<sub>TM</sub> Cellulose tape (+16.3%)
- Masking tape (+11.0%)

# Medium-term Management Plan "CREATION 2026"



	CREATION 2026								
	FY2024 Plan	FY2024 Results	FY2025 Plan	FY2025 Forecast	FY2026 Plan				
Net sales (Billions of yen)	486	494	500	515	530				
Operating Profit (Billions of yen)	24	25	32	30	45				
Ordinary Profit (Billions of yen)	25	26	33	31	46				
Profit attributable to owners of parent (Billions of yen)	19	19	25	20	35				
ROE		4.6%		_	8% or more				
Global sales ratio	_	10.5%	_	_	15%				
New products ratio	_	10.7%	_	_	15%				

# "CREATION 2026" Priority Themes





# Restructuring of the business portfolio

- (1) Fundamental Improvement in Profitability in the **Tape Business Segment**
- (2) Allocation of Management Resources to Growth **Businesses and New Business Fields**





### **Globalization**

- (1) Pursue Growth of the Three Sales Bases
- (2) Expand Functions to Achieve a 30% Global Sales Ratio in FY2030
- (3)Promote Globalization Across the Entire Group



# **Human capital management**

- (1)Promote Diversity, Equity & Inclusion (DE&I)
- (2) Develop Autonomous Human Resources Capable of **Self-Transformation and Growth**
- (3)Improve Employee Health and Engagement
- (4)Introduce a New Human Resources System

# Cash dividends



		Annual	dividends per	Total cash	D	Ratio of		
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total	dividends (Total)	Payout ratio (Consolidated)	dividends to net assets (Consolidated)
	Yen	Yen	Yen	Yen	Yen	Millions of yen	%	%
Fiscal year ended March 31, 2024	-	0.00	-	35.00	35.00	712	39.3	1.7
Fiscal year ended March 31, 2025	-	0.00	-	35.00	35.00	712	36.4	1.7
Fiscal year ending March 31, 2026 (Forecast)	-	0.00	-	40.00	40.00		-	



# Sticking to your needs

# NICHIBAN Corporate Information

https://www.nichiban.com/corp/



### **Integrated Report 2024**

https://www.nichiban.com/corp/sustainability/report/



This document contains the Company's current plans and earnings forecasts. These plans and projections are based on information currently available and are subject to change. Actual results may differ from these plans due to various conditions and factors in the future, and this document does not guarantee the realization of the plan. This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.